Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

bioAffinity Technologies, Inc.

NASDAQ: BIAF · Industrial Applications and Services · 12 alerts · CIK 1712762

Share price
$2.00Close, Nov 16
Market cap
$3.64M
Shares outstanding
1.82MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Services-Commercial Physical & Biological ResearchSIC 8731

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All bioAffinity Technologies, Inc. filings on SEC EDGAR ↗

5:29 PM ET 8-K
Financial Results

bioAffinity Technologies Financial Results

bioAffinity Technologies reported its Q3 2026 financial results, highlighted by a 79% year-to-date increase in CyPath Lung testing revenue to $1.1 million. The company saw a 100% increase in test unit sales and an 89% increase in the number of ordering physicians compared to the prior year. Management noted continued momentum in commercialization and expansion of its government healthcare distribution network.

Term
Q3 2026

“Our third quarter results reflect the growing clinical adoption of CyPath® Lung as a vital tool for the early detection of lung cancer. With test unit sales doubling year-to-date and a significant increase in our physician base, we are seeing the direct impact of our commercial strategy and the clear need for noninvasive diagnostic solutions in the lung cancer care continuum.”

Maria Zannes, President and Chief Executive Officer
5:28 PM ET 10-Q
Financial Results

bioAffinity Technologies Q3 2026 Results: Net Loss of $5.28M, Loss Widens

For the nine months ended September 30, 2026, bioAffinity Technologies reported a net loss of $12.3 million on revenue of $3.9 million, compared to a net loss of $11.8 million on revenue of $4.6 million in the prior year period. The company's cash position decreased significantly to $2.6 million from $6.4 million at year-end 2025, driven by increased operating expenses in clinical development and general administration.

Key figure
Net loss $5.28M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.